In its appendix on Life Science, Dagens Industri draws attention to two Advantum customers who have real wind in their sails, NorthX Biologics and BioArctic.
NorthX Biologics offers companies from all over the world to process develop their products in their facility in Matfors. The mission from Vinnova is to develop an innovation hub for the development of both new vaccines and advanced drugs in Sweden, and the work is already in full swing before the opening. The large facility is GMP certified and for several years now the company has been using the Advantum Life Science Suite to manage its regulatory documentation.
BioArctic has after two decades of research made a breakthrough in the field of Alzheimer's. The company has developed the world's first Alzheimer's drug, Leqembi, which affects the disease process and it is expected to reach the market soon. The drug has received accelerated approval by the FDA and will be available on the US market shortly. After that, more markets await. BioArctic uses the Advantum Life Science Suite for regulatory documentation management.
Learn more about Advantum Life Science Suite here: Life Science Suite - Advantum
If you want to read the articles in DI, the links are here: